CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES FROM PURIFIED HUMAN CD4+ AND CD8+ T-LYMPHOCYTES

被引:61
作者
TENOR, H
STANICIU, L
WENDEL, A
SCHUDT, C
DJUKANOVIC, R
HATZELMANN, A
CHURCH, MK
SHUTE, JK
机构
[1] UNIV SOUTHAMPTON,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND
[2] UNIV KONSTANZ,FAC BIOL,W-7750 CONSTANCE,GERMANY
[3] BYK GULDEN LOMBERG GMBH,CONSTANCE,GERMANY
关键词
PHOSPHODIESTERASE; T-LYMPHOCYTES; AIRWAY INFLAMMATION; CYTOKINE EXPRESSION;
D O I
10.1111/j.1365-2222.1995.tb01109.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background CD4(+) and CD8(+) T-lymphocytes are suggested to differentially affect airway inflammation in asthma. Agents which increase intracellular cAMP levels, such as PDE inhibitors, have been shown to diminish lymphocyte growth and differentiation, and to affect cytokine expression. Differences in the PDE isoenzyme profile between CD4(+) and CD8(+) cells might form a basis to differentially modify their functions by PDE inhibitors. Objective The study investigates and compares the PDE isoenzyme activity profiles of human peripheral blood CD4(+) and CD8(+) T-lymphocytes. Methods CD4(+) and CD8(+) T-lymphocytes were purified (>98%) from peripheral brood mononuclear cells by negative selection. PDE isoenzyme activity profiles were investigated using PDE isoenzyme selective inhibitors and activators. Results In CD4(+) and CD8(+) T-lymphocyte homogenates, PDE IV and PDE III activities were the predominant PDE isoenzyme activities at 0.5 mu M cyclic nucleotide substrate concentrations. PDE IV was localized in the soluble fraction whereas PDE III was membrane bound. Low PDE I, II and V activities were detected. About 20% of total cAMP hydrolysing capacity at 0.5 mu M cAMP was insensitive to PDE isoenzyme selective inhibitors and activators and therefore could not be assigned to PDE I-IV. The PDE isoenzyme pattern was not different between CD4(+) and CD8(+) T-lymphocytes. Moreover, representative inhibitors of PDE III and IV activity inhibited cAMP hydrolysis in soluble fractions of both T-lymphocyte subsets with similar potency. Enzyme kinetic analysis similarly did not reveal differences between CD4(+) and CD8(+) T-lymphocytes. Conclusion Normal CD4(+) and CD8(+) T-lymphocytes are likely to be equally sensitive targets for the effects of PDE inhibitors.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 37 条
[1]  
BARNES PJ, 1992, EUR RESPIR J, V5, P1126
[2]   AN IMPROVED ASSAY OF CYCLIC 3',5'-NUCLEOTIDE PHOSPHODIESTERASES WITH QAE-SEPHADEX COLUMNS [J].
BAUER, AC ;
SCHWABE, U .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1980, 311 (02) :193-198
[3]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[4]   INCREASES IN ACTIVATED T-LYMPHOCYTES, EOSINOPHILS, AND CYTOKINE MESSENGER-RNA EXPRESSION FOR INTERLEUKIN-5 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN BRONCHIAL BIOPSIES AFTER ALLERGEN INHALATION CHALLENGE IN ATOPIC ASTHMATICS [J].
BENTLEY, AM ;
MENG, Q ;
ROBINSON, DS ;
HAMID, Q ;
KAY, AB ;
DURHAM, SR .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 8 (01) :35-42
[5]  
BLOOM TJ, 1994, FASEB J, V8, pA372
[6]   THE CATALYTIC SUBUNIT OF PROTEIN KINASE-A TRIGGERS ACTIVATION OF THE TYPE-V CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE FROM GUINEA-PIG LUNG [J].
BURNS, F ;
RODGER, IW ;
PYNE, NJ .
BIOCHEMICAL JOURNAL, 1992, 283 :487-491
[7]   IMMUNOCHEMICAL CHARACTERIZATION OF THE DISTINCT MONOCYTE CYCLIC AMP-PHOSPHODIESTERASE FROM PATIENTS WITH ATOPIC-DERMATITIS [J].
CHAN, SC ;
REIFSNYDER, D ;
BEAVO, JA ;
HANIFIN, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 91 (06) :1179-1188
[8]   INHIBITION OF EOSINOPHIL CYCLIC-NUCLEOTIDE PDE ACTIVITY AND OPSONISED ZYMOSAN-STIMULATED RESPIRATORY BURST BY TYPE-IV-SELECTIVE PDE INHIBITORS [J].
DENT, G ;
GIEMBYCZ, MA ;
RABE, KF ;
BARNES, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (02) :1339-1346
[9]  
EPSTEIN P, 1984, ADV CYCLIC NUCL PROT, P304
[10]   COULD ISOENZYME-SELECTIVE PHOSPHODIESTERASE INHIBITORS RENDER BRONCHODILATOR THERAPY REDUNDANT IN THE TREATMENT OF BRONCHIAL-ASTHMA [J].
GIEMBYCZ, MA .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (10) :2041-2051